Redmile Group, LLC - Insider Trading & Ownership

Entity
Company
Location
One Letterman Drive, Building D, Suite D3 300, San Francisco, CA
Summary
The estimated value of insider holdings of Redmile Group, LLC is at least $638M dollars as of December 16, 2024. Redmile Group, LLC is the 10%+ Owner of ADC Therapeutics SA and owns shares of ADC Therapeutics SA (ADCT) stock worth about $220M. Redmile Group, LLC is the 10%+ Owner of RayzeBio, Inc. and owns shares of RayzeBio, Inc. stock worth about $116M. Redmile Group, LLC is the Director, 10%+ Owner of IGM Biosciences, Inc. and owns shares of IGM Biosciences, Inc. (IGMS) stock worth about $83.1M. Redmile Group, LLC is the Director, 10%+ Owner of FATE THERAPEUTICS INC and owns shares of FATE THERAPEUTICS INC (FATE) stock worth about $75.8M. Redmile Group, LLC is the Director of Absci Corp and owns shares of Absci Corp (ABSI) stock worth about $41.1M. Redmile Group, LLC is the 10%+ Owner of Entrada Therapeutics, Inc. and owns shares of Entrada Therapeutics, Inc. (TRDA) stock worth about $31.3M. Redmile Group, LLC is the 10%+ Owner of Zymeworks Inc. and owns shares of Zymeworks Inc. (ZYME) stock worth about $30.6M. Redmile Group, LLC is the 10%+ Owner of Verve Therapeutics, Inc. and owns shares of Verve Therapeutics, Inc. (VERV) stock worth about $19.4M. Redmile Group, LLC is the 10%+ Owner of Adagio Therapeutics, Inc. and owns shares of Invivyd, Inc. (IVVD) stock worth about $13.4M. Redmile Group, LLC is the Director, 10%+ Owner of Shattuck Labs, Inc. and owns shares of Shattuck Labs, Inc. (STTK) stock worth about $6.92M.
All Insider Reports
All Insider Reports

Ownership of Redmile Group, LLC

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
ADCT ADC Therapeutics SA 10%+ Owner $220M +$71.5M +48% Dec 11, 2024
RYZB RayzeBio, Inc. 10%+ Owner $116M Sep 19, 2023
IGMS IGM Biosciences, Inc. Director, 10%+ Owner $83.1M Sep 30, 2024
FATE FATE THERAPEUTICS INC Director, 10%+ Owner $75.8M +$166K +0.22% Dec 12, 2024
ABSI Absci Corp Director $41.1M +$1M +2.49% Jun 12, 2024
TRDA Entrada Therapeutics, Inc. 10%+ Owner $31.3M Nov 2, 2021
ZYME Zymeworks Inc. 10%+ Owner $30.6M Oct 13, 2022
VERV Verve Therapeutics, Inc. 10%+ Owner $19.4M Jun 21, 2021
IVVD Invivyd, Inc. 10%+ Owner $13.4M Aug 10, 2021
STTK Shattuck Labs, Inc. Director, 10%+ Owner $6.92M $0 0% Dec 4, 2024
AUGX Augmedix, Inc. Director, 10%+ Owner $0 Oct 2, 2024
SNCE Science 37 Holdings, Inc. Former 10% Owner and Director $0 Mar 12, 2024
MDVLQ MedAvail Holdings, Inc. Director, 10%+ Owner Jun 16, 2023

Insider Transactions Reported by Redmile Group, LLC:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.